At the heart of this discovery lies a preclinical study, published in the prestigious journal Cell, where UCLA Neuromodulation Division scientists have pioneered a unique animal model closely mimicking human TMS treatment protocols. This model allows direct stimulation of the awake mouse brain using accelerated intermittent theta burst stimulation (aiTBS), a cutting-edge TMS variant capable of delivering rapid therapeutic benefits in mere days instead of weeks. By harnessing advanced real-time neural imaging coupled with behavioral assays, the team deciphered how aiTBS achieves swift and durable antidepressant effects at the synaptic and circuit level.

Chronic stress, widely regarded as a critical etiological factor in depression, was shown to inflict damage on the prefrontal cortex’s intricate neuronal architecture, specifically through the loss of dendritic spines—microscopic protrusions critical for synaptic communication. This synaptic degradation was not uniform but affected various neuron types across the cortical landscape. Complementing these structural deficits were related functional impairments in neural circuit dynamics, which collectively underpin the maladaptive behaviors characteristic of depressive states.

The UCLA researchers made a staggering observation: just a single day of aiTBS reversed these synaptic deficits—but with striking specificity. The restoration was confined almost exclusively to intratelencephalic (IT) neurons, a distinct subset of excitatory cortical cells known for their role in mediating long-range cortical communication. Unlike IT neurons, neighboring neuron classes remained largely impervious to stimulation, revealing a cell type-specific mechanism previously unappreciated in the context of brain stimulation therapies.

Critically, the re-emergence of dendritic spines in IT neurons coincided with enhanced neural activity during depression-associated behaviors, suggesting a direct link between synaptic structural repair, circuit reactivation, and behavioral improvement. This precision targeting challenges the pervasive assumption that TMS produces broad, indiscriminate excitation across the prefrontal cortex. Instead, it highlights the nuanced modulation of discrete neuronal populations as the therapeutic driver.

In a series of elegant causal experiments, the team employed selective inhibition of IT neurons during aiTBS sessions and found that blocking their activity abolished the antidepressant outcomes. This demonstrated unequivocally that IT neuron engagement is indispensable for the observed behavioral recovery, illuminating a vital biological substrate for TMS efficacy. The data underscore a mechanistic framework wherein the restoration of dendritic spine integrity in IT neurons reestablishes the neurocircuitry essential for adaptive mood regulation.

Furthermore, the therapeutic effects manifested rapidly, with behavioral metrics improving markedly within 24 hours post-treatment, and these benefits endured for at least one week following a single stimulation session. This durable response was mirrored by stable synaptic changes in IT neurons, suggesting that aiTBS fosters lasting neuroplastic remodeling rather than transient neural excitation. Such sustained circuit restoration offers hope for more effective, time-efficient interventions for depression.

Beyond advancing the fundamental understanding of TMS, these findings hold profound clinical implications. Current repetitive TMS protocols necessitate daily sessions over multiple weeks—a logistical and financial burden for many patients. The demonstrated efficacy of accelerated protocols in animal models heralds a future wherein treatment could be compressed into shorter timeframes without sacrificing, and possibly enhancing, therapeutic potency.

Moreover, the revelation of neuron-specific targeting prompts a paradigm shift toward precision neuromodulation. It opens avenues to refine stimulation parameters tailored to engage critical cell types implicated in various psychiatric and neurological disorders, potentially broadening the therapeutic scope of TMS. Conditions such as obsessive-compulsive disorder, post-traumatic stress disorder, chronic pain syndromes, and tinnitus—each linked to circuit dysregulation—may benefit from such targeted strategies.

This research also exemplifies the power of translational neuroscience, bridging clinical observations with cellular-level mechanisms. Dr. Scott Wilke, a psychiatrist and neuromodulation expert at UCLA Health, emphasized the fusion of clinical insights with avant-garde neuroscience tools as a roadmap to individualized therapies. By dissecting how distinct stimulation paradigms sculpt neuronal networks in animal models, the field moves closer to personalized brain stimulation protocols optimized for maximal efficacy and durability.

While acknowledging that mouse models cannot fully replicate the complexity of human depressive illness, the study represents a leap forward in demystifying TMS’s mode of action. It delivers compelling evidence that TMS’s rapid antidepressant effects are underpinned by the selective restoration of synaptic architecture in IT neurons, enabling functional recovery of disrupted brain circuits. This paradigm not only deepens scientific understanding but also inspires future innovations in neuromodulation technology.

Ultimately, these findings ignite hope for millions worldwide suffering from depression and other refractory neuropsychiatric conditions. By unveiling the precise cellular targets and mechanisms of TMS, UCLA’s research lays the foundation for more efficient, precise, and enduring brain stimulation therapies. As neuromodulation continues to evolve, such mechanistic clarity will be essential in transforming experimental treatments into standard clinical practice, ushering in a new era of mental health care.

Subject of Research: Animals

Article Title: A cell type-specific mechanism driving the rapid antidepressant effects of transcranial magnetic stimulation

News Publication Date: 7-May-2026

COI Statement: The authors declare no competing interests.

Keywords: Transcranial magnetic stimulation, medical treatments, depression, mental health, psychological stress, clinical psychology, psychological science, anxiety

The hippocampus, nestled deep within the medial temporal lobe, plays a pivotal role in encoding new memories and shaping emotional responses. Aberrations in hippocampal circuitry underpin a host of debilitating neurological and psychiatric disorders, including Alzheimer’s disease, major depressive disorder, anxiety syndromes, and post-traumatic stress disorder (PTSD). Historically, direct manipulation of hippocampal activity has been limited to invasive methods such as deep brain stimulation or pharmacological interventions with broad systemic effects, posing significant risks and limited precision.

This novel study employed cutting-edge technology to surmount these challenges by coupling noninvasive TMS with real-time intracranial recordings and neuroimaging. The research team capitalized on a rare clinical opportunity afforded by eight neurosurgical patients who had intracranial electrodes implanted in their hippocampi for medical reasons. Through this unique setup, they could administer single-pulse and repetitive TMS to cortical regions while simultaneously measuring immediate electrophysiological responses deep within the hippocampus via intracranial electroencephalography (iEEG).

A defining feature of this investigation was the emphasis on personalized neuromodulation. Rather than relying on conventional, one-size-fits-all stimulation targets, the researchers harnessed resting-state functional magnetic resonance imaging (fMRI) to map each individual’s unique functional connectivity profile between the hippocampus and accessible cortical sites. This stratagem allowed precise identification of parietal cortex locations most strongly coupled to the hippocampus, enabling a tailored stimulation approach designed to maximize engagement of hippocampal networks.

Findings revealed a remarkable enhancement in hippocampal activation when TMS pulses were delivered to these individualized cortical hotspots. Patients with connectivity-informed stimulation sites exhibited robust hippocampal electrophysiological responses, whereas those receiving stimulation at generic cortical sites did not show significant modulation. Importantly, this disparity underscores the critical role of functional connectivity as a biomarker for effective and targeted neuromodulation.

To extend these insights beyond the clinical population, the researchers conducted a parallel noninvasive experiment involving 79 neurologically healthy volunteers undergoing simultaneous TMS and fMRI. Although individual connectivity-guided targeting was not applied in this cohort, analyses demonstrated a compelling correlation: stronger intrinsic functional connectivity between the stimulation sites and the hippocampus predicted more pronounced TMS-evoked hippocampal responses. Furthermore, proximity of the stimulation site to the personalized target map also positively influenced the neuromodulatory efficacy.

These comprehensive multimodal data collectively illustrate that harnessing an individual’s unique brain connectivity can improve the precision, magnitude, and reliability of hippocampal neuromodulation. This representa a critical leap forward in circuit-based brain stimulation therapies, enabling interventions that may be tailored to the specific neuroanatomical and functional architecture of each patient’s brain.

Dr. Jing Jiang, the senior author and an assistant professor at the UI College of Pediatrics and Psychiatry, highlights the transformative potential of this approach: “The hippocampus has always been a challenging target due to its deep location and complex circuitry. Our findings provide a proof-of-concept that noninvasive, personalized stimulation can modulate hippocampal function safely and effectively, potentially opening new avenues for treating a range of neurological and psychiatric conditions.”

The methodological innovation underpinning this research—simultaneous TMS combined with intracranial electrophysiological and fMRI monitoring—allowed unprecedented temporal and spatial resolution in assessing the immediate effects of brain stimulation. This integrative paradigm enables researchers to dissect the causal pathways through which cortical stimulation propagates to deeper subcortical structures.

Moreover, the ability to tailor stimulation sites according to an individual’s resting-state brain connectivity map moves beyond traditional trial-and-error approaches, positioning functional connectivity as an essential biomarker for therapeutic targeting. This sets the stage for personalized neuromodulation therapies that could be optimized to enhance efficacy and predict patient-specific responses.

The implications of this work are far-reaching. By demonstrating the feasibility of noninvasive hippocampal modulation, it paves the way for the development of novel therapeutic modalities to combat memory impairments in Alzheimer’s disease, alleviate symptoms of depression and anxiety, and potentially ameliorate trauma-related disorders. Furthermore, this approach alleviates the risks associated with invasive implantation of electrodes, such as infection or tissue damage.

The research team included a multidisciplinary ensemble of experts, with contributions from neuroscientists, clinicians, and engineers, underscoring the collaborative nature of modern brain research. Funding support came from prominent institutions including the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, emphasizing the significance of this research trajectory for public health.

Looking ahead, this pioneering demonstration invites further clinical trials to evaluate the long-term efficacy and therapeutic potential of personalized TMS protocols targeting the hippocampus. Such work will refine stimulation parameters, optimize patient selection based on individual connectivity profiles, and expand understanding of the mechanistic underpinnings governing brain network modulation in health and disease.

In summary, the University of Iowa Health Care team’s research inaugurates a new era in noninvasive brain stimulation, where personalized functional neuroimaging guides the precise engagement of deep brain structures like the hippocampus. This innovation holds promise for revolutionizing treatments for a variety of disorders rooted in hippocampal dysfunction, translating neuroscience breakthroughs into tangible clinical benefits.

Subject of Research: People
Article Title: Multimodal evidence for hippocampal engagement and modulation by functional connectivity-guided parietal TMS
News Publication Date: 8-Mar-2026
Web References: https://www.nature.com/articles/s41467-026-70346-x
Image Credits: Jing Jiang Lab, University of Iowa Health Care

Keywords: Transcranial magnetic stimulation, Hippocampus, Electroencephalography, Psychiatric disorders, Neuroimaging